BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 14508882)

  • 1. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T; Anaissie E
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive fungal infections in liver transplantation.
    Liu X; Ling Z; Li L; Ruan B
    Int J Infect Dis; 2011 May; 15(5):e298-304. PubMed ID: 21345708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The place for itraconazole in treatment.
    Maertens J; Boogaerts M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances and challenges in the treatment of invasive fungal infections.
    Shao PL; Huang LM; Hsueh PR
    Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR; Slavin MA; Donnelly JP
    Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
    Murali S; Langston A
    Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early diagnosis of fungal infection in immunocompromised patients.
    Barnes RA
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i3-6. PubMed ID: 18063601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
    Salavert M
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G; Kontoyiannis DP
    Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
    Leather HL; Wingard JR
    Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
    Doubek M; Mayer J; Horký D; Doubek J; Rácil Z; Vorlícek J
    Vnitr Lek; 2002 Mar; 48(3):248-54. PubMed ID: 11968587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Up-date on the treatment of serious fungal infections].
    Borges Sa M
    Rev Esp Quimioter; 2008; 21 Spec No 1():14-25. PubMed ID: 18752076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal prophylaxis for invasive mycoses in high risk patients.
    Ullmann AJ; Cornely OA
    Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts.
    Hathorn JW
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):1051-99. PubMed ID: 8226565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing epidemiology of systemic fungal infections.
    Richardson M; Lass-Flörl C
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.